Some US drug developers jump after FDA announces recipients of national priority vouchers

Disc Medicine

17/10/2025 15:12

Updates

** Shares of drug developers Revolution Medicines RVMD.O up 11.7% at $55.48, Achieve Life Sciences' ACHV.O gains 34.4% to 4.13%, and Disc Medicine's IRON.O rises 28.3% to $95.43

** Late on Thursday, U.S. FDA announced nine products under a new fast-track review process

** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months

** Products include RVMD's daraxonrasib for pancreatic cancer, ACHV's cytisinicline for nicotine dependence related to e-cigarette or vaping use and IRON's bitopertin for porphyria

** Brokerage Oppenheimer says daraxonrasib's first approval could come as early as mid-2026

** Eli Lilly's LLY.N experimental weight-loss pill, orforglipron, was expected to be included in the list

** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered

** LLY shares down 2.1%

** Including session moves, RVMD up 24.3%, IRON up 40%, LLY up ~3% and ACHV up 9.9% YTD

(Reporting by Christy Santhosh and Siddhi Mahatole)

((Christy.Santhosh@thomsonreuters.com))